BUDESHINE F 400 CAP: Formoterol & Budesonide for Moderate-to-Severe Asthma & COPD

 BUDESHINE F 400 CAP, manufactured by Steris Healthcare, is a combination inhalation therapy containing Formoterol Fumarate Dihydrate IP 6 mcg and Budesonide IP 400 mcg, delivered via a rotacaps/dry powder inhaler system. It is prescribed for the regular maintenance treatment of bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) in patients who require both sustained bronchodilation and anti-inflammatory control. Formoterol is a long-acting beta-2 agonist (LABA) that provides prolonged bronchodilation, while budesonide is an inhaled corticosteroid that reduces the chronic airway inflammation underlying persistent respiratory symptoms. This higher-strength 400 mcg budesonide combination is typically reserved for patients with moderate to severe asthma or COPD requiring a higher level of anti-inflammatory control.

Why It's Important

Patients with moderate to severe persistent asthma or COPD often experience inadequate symptom control with lower-dose inhaled corticosteroid therapy alone, leading to frequent exacerbations, nighttime symptoms, and reduced exercise tolerance. Combining a long-acting bronchodilator with a higher-strength corticosteroid in a single inhaler simplifies the treatment regimen while ensuring both the inflammatory and bronchoconstrictive components of the disease are addressed simultaneously. This dual-action approach with BUDESHINE F 400 CAP is important for patients who need step-up therapy beyond basic maintenance treatment, helping reduce exacerbation frequency, improve lung function, and support better day-to-day respiratory stability.

Key Benefits 

What are the benefits?

• Provides sustained, long-acting bronchodilation for 12+ hours
• Higher-strength budesonide offers enhanced anti-inflammatory control
• Reduces frequency of asthma and COPD exacerbations
• Simplifies treatment with a single combination inhaler device
• Manufactured under WHO-GMP and ISO 9001:2018 certified facility standards by Steris Healthcare, ensuring consistent potency and quality

Side Effects

Common side effects may include throat irritation, hoarseness, headache, mild tremors, palpitations, or oral thrush if the mouth is not rinsed after inhalation.

Serious Side Effects 

Seek immediate medical attention for significant increase in heart rate, chest pain, signs of a severe allergic reaction, worsening breathlessness immediately after use (paradoxical bronchospasm), or signs of adrenal suppression with prolonged high-dose use such as unusual fatigue or low blood pressure.

Available Substitute 

Several branded formoterol and budesonide combination inhaler formulations are available in the Indian market at comparable strengths. Brand or device switches should only be made under physician guidance, as inhaler technique and device design can affect drug delivery consistency.

Dosage Guidelines 

Dosage is individualized by the treating physician based on disease severity and response, typically one inhalation twice daily via the rotacaps device. Patients should be trained on proper inhaler technique to ensure effective drug delivery, and should rinse the mouth after each use. Missed doses should not be doubled.

Precautions & Warnings

Use cautiously in patients with cardiovascular disease, hypertension, diabetes, or hyperthyroidism due to the formoterol component. Caution is also advised in patients with active respiratory infections or ocular herpes simplex due to the corticosteroid component. Avoid abrupt discontinuation; taper under physician guidance.

Mechanism of Action

Formoterol acts as a long-acting beta-2 adrenergic agonist, relaxing bronchial smooth muscle through increased cyclic AMP. Budesonide binds to intracellular glucocorticoid receptors, suppressing inflammatory gene transcription and reducing airway inflammation, mucosal edema, and hyperresponsiveness.

Conclusion

BUDESHINE F 400 CAP by Steris Healthcare offers a robust combination therapy for patients requiring higher-strength anti-inflammatory and long-acting bronchodilator control in asthma and COPD management. Treatment should be initiated and monitored under physician guidance for optimal respiratory outcomes.